The myeloproliferative neoplasms (MPNs) are chronic hematological malignancies originating at the level of the pluripotent hematopoietic stem cell (HSC). This unique assembly of both laboratory and clinical MPN investigators coupled with the infrastructure to conduct independent, investigator-initiated, multicenter, trials has proven to be rewarding over the last 10 years of continuous NCI-funding and is poised to continue to further evolve. Keeping in mind the constructive reviewer comments, we have concentrated our clinical efforts into a stronger and more nimble consortium of 9 core clinical sites based solely in North America with established centers of excellence in MPN. The new application for Project 4 (formerly Project 6) is focused on myelofibrosis (MF) the MPN with the most limited survival and the clinical translation of mechanism based therapeutics derived from disease targets identified in Projects 1-3. An initial wave of early phase, single agent clinical trials (MPN-RC 116-118) will be conducted in years 1-3 and then three innovative combination therapy trials derived from supportive pre-clinical data and single agent tolerability and signal of activity will be pursued in years 3-5 (MPN-RC 119-123). Additionally, primary MPN tissue will be acquired through the MPN-RC tissue procurement protocol (Core B) and genomically characterized (Core D) from patients seen at all sites for distribution to Projects 1-3. Each trial will also have study schedule-specific, protocol driven, biomarkers to determine 1) effect on MPN HSC burden through mutational and cytogenetic analysis; 2) confirmation of proposed therapeutic mechanism of action through drug specific pharmacodynamic studies; 3) restoration of normal bone marrow microenvironment through histomorphologic analysis and cytokine expression profiles. The overarching goal of Project 4 is to test agents and innovative approaches that alone or in combination delete the MF HSC and favorably modify the MF-supporting microenvironment, thereby, altering the natural history of MF and improving patient outcome.
The specific aims i nclude 1) Annually obtain peripheral blood from MF patients in order to provide molecularly characterized tissue specimens that will be utilized for the investigations planned in Projects 1-3; 2) Conduct early phase clinical trials years 1-3 utilizing agents targeting the MPN HSC that have mechanistic rationales originating from Projects 1-3; 3) Evaluate therapeutic agents in early phase clinical trials years 1-3 that can interrupt the MF HSC supporting tumor microenvironments and, thereby, restore a bone marrow niche favoring normal hematopoiesis; 4) Utilize agents from Phase I/II trials associated with Aims 2 and 3 that can be tested in combination therapy approaches in years 3-5. The close interaction among the scientific projects, biostatistical, administrative, tissue bank, and biomarker cores with Project 4 embodies the true potential for translational research in MF that only the MPN-RC can provide.
The overall goal of this project is to directly translate therapies originating from therapeutic targets identified from scientific Projects 1-3 into novel treatment strategies targeting the myeloproliferative neoplasm (MPN) hematopoietic stem cell (HSC) and the supportive microenvironmental abnormalities in patients with myelofibrosis (MF). Such therapies will be evaluated in investigator-initiated, early developmental phase, clinical trials with agents derived from the scientific Projects (1-3) and designed to deplete the MPN HSC through direct anti- clonal activity and modification of the impaired microenvironment, thereby favorably altering the natural history of disease.
|Gilles, Laure; Arslan, Ahmet Dirim; Marinaccio, Christian et al. (2017) Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 127:1316-1320|
|Varricchio, Lilian; Falchi, Mario; Dall'Ora, Massimiliano et al. (2017) Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function. Front Cell Dev Biol 5:96|
|Zingariello, M; Sancillo, L; Martelli, F et al. (2017) The thrombopoietin/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J 7:e572|
|Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2017) The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp Hematol 50:53-76|
|Lanikova, Lucie; Reading, N Scott; Hu, Hao et al. (2017) Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget 8:11739-11747|
|Sergueeva, Adelina; Miasnikova, Galina; Shah, Binal N et al. (2017) Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica 102:e166-e169|
|Wang, Linghua; Wheeler, David A; Prchal, Josef T (2016) Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 44:644-52|
|Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222|
|Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12|
|Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82|
Showing the most recent 10 out of 181 publications